+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Infusion of branched-chain enriched amino acid solution in patients with hepatic encephalopathy



Infusion of branched-chain enriched amino acid solution in patients with hepatic encephalopathy



Annals of Surgery 196(2): 209-220



Hospitalized patients with hepatic insufficiency often suffer from severe catabolic states and are in urgent need of nutritional support during their acute illness. Protein intolerence, however, remains a significant problem with respect to the provision of adequate nutrition, either enterally or parenterally. The following report is an anecdotal series of 63 consecutive patients in a large urban hospital treated prospectively with nutritional support using a prototype high branched-chain amino acid solution (FO80) given by technique of total parenteral nutrition by the subclavian or internal jugular route with hypertonic dextrose. Sixty-three patients, of which 42 had chronic liver disease (cirrhosis) with acute decompensation and 17 with acute hepatic injury as well as four with hepatorenal syndrome, are the subject of this report. All required intravenous nutritional support and were either intolerant to commercially available parenteral nutrition solutions or were in hepatic encephalopathy at the time they were initially seen. The cirrhotic patients had been hospitalized for a mean of 14.5 +/- 1.9 days before therapy, had a mean bilirubin of 13 mg/100 ml, and had been in coma for 4.8 +/- 0.7 days despite standard therapy. Patients with acute hepatitis had been in the hospital for 16.2 +/- 4.1 days before therapy, had a mean bilirubin of 25 mg/100 ml, and had been in coma 5.2 +/- 1.6 days before therapy. Routine tests of liver function, blood chemistries, amino acids, EEGs, and complex neurological testing including Reitan trailmaking tests were used in the evaluation of these patients. Up to 120 grams of synthetic amino acid solution with hypertonic dextrose was tolerated in these patients with improvement noted in encephalopathy of at least one grade in 87% of the patients with cirrhosis and 75% of the patients with hepatitis. Nitrogen balance was achieved when 75 to 80 grams of synthetic amino acids were administered. Survival was 45% in the cirrhotic group and 47% in the acute hepatitis group. Encephalopathy appeared to correlate with individual amino acids differentially in the various groups and with the ratio between the aromatic and the branched-chain amino acids. Ammonia did not correlate with either the degree of encephalopathy or improvement therefrom. In 24 Patients therapy for hepatic encephalopathy was limited to infusion of the branched-chain enriched amino acid solution only, with wake-up in 66% of this group. The results strongly suggest that in protein intolerant patients requiring nutritional support, infusion with branchedchain enriched amino acid solutions is well tolerated with either no worsening of or improvement in hepatic encephalopathy coincident with the achievement of nitrogen equilibrium and adequate nutritional support.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 043407976

Download citation: RISBibTeXText

PMID: 6284073


Related references

Effect of branched chain amino acid enriched amino acid solution on normalization of plasma amino acids in hepatic encephalopathy. Taiwan yixuehui zazhi 84(3): 331-338, 1985

Pharmacological studies of branched chain amino acid and arginine enriched amino acid solution mhs 2 for the treatment of hepatic encephalopathy effect on the ammonia metabolism in pca rats. Japanese Journal of Pharmacology 52(Suppl. 1): 336P, 1990

Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis. Journal of Hepatology 10(3): 291-296, 1990

Infusion of Branched-chain Enriched Amino Acid Solution in. Annals of Surgery 196(2): 209-220, 1982

Nutrient-induced thermogenesis and protein-sparing effect by rapid infusion of a branched chain-enriched amino acid solution to cirrhotic patients. Journal of Medicine 27(3-4): 176-182, 1996

Effects of a branched-chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs. Metabolic Brain Disease 14(2): 103-115, 1999

Branched chain enriched amino acid solutions in the treatment of hepatic encephalopathy a controlled trial. Italian Journal of Gastroenterology 17(1): 5-10, 1985

Hyperprolactinemia in hepatic encephalopathy: the effect of infusion of an amino acid mixture with excess branched chain amino acids. Hepato-Gastroenterology 30(5): 174-177, 1983

Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomized, prospective trial. Surgery 104(3): 482-488, 1988

Evaluation of an infusion solution enriched with branched chain amino acid in parenteral nutrition of rats. Journal of Nutrition 110(4): 710-719, 1980

Evaluation of an Infusion Solution Enriched with Branched Chain Amino Acid in Parenteral Nutrition of Rats. The Journal of Nutrition 110(4): 710-719, 1980

Effects of branched chain amino acids infusion on patients with hepatic encephalopathy. Japanese Journal of Medicine 21(4): 269, 1982

Treatment of hepatic encephalopathy with branched chain amino acid enriched solutions a review of randomized controlled trials. Adibi, S A Et Al (Ed ) Branched Chain Amino And Keto Acids in Health And Disease; International Symposium, Goettingen, West Germany, Oct 21-23, 1983 Xiv+571p S Karger: Basel, Switzerland; New York, N Y , Usa Illus 497-504, 1984

Chronic hepatic encephalopathy. Long-term therapy with a branched-chain amino-acid-enriched elemental diet. JAMA 242(4): 347-349, 1979

Pharmacological studies of a new amino acid solution mhs 2 for the treatment of hepatic encephalopathy influence of branched chain amino acid on brain amine metabolism in pca rats. Japanese Journal of Pharmacology 55(Suppl. 1): 104P, 1991